KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma

被引：0
|
作者：
Ascierto, P. A. [1 ]
Ferrucci, P. F. [2 ]
Stephens, R. [3 ]
Del Vecchio, M. [4 ]
Atkinson, V. [5 ]
Schmidt, H. [6 ]
Schachter, J. [7 ]
Queirolo, P. [8 ]
Long, G. V. [9 ]
Di Giacomo, A. M. [10 ]
Svane, I. [11 ]
Lotem, M. [12 ]
Bar-Sela, G. [13 ]
Couture, F. [14 ]
Mookerjee, B. P. [15 ]
Ghori, R. [16 ]
Ibrahim, N. [16 ]
Moreno, B. Homet [16 ]
Ribas, A. [17 ]
机构：
[1] Ist Nazl Tumori Fdn G Pascale, Melanoma Canc Immunotherapy & Dev Therapeut Unit, Naples, Italy
[2] Ist Europeo Oncol, Oncol, Milan, Italy
[3] Auckland City Hosp, Med Oncol, Auckland, New Zealand
[4] Fdn IRCCS Ist Nazl Tumori, Med Oncol, Milan, Italy
[5] Greenslopes Private Hosp, Gallipoli Med Res Fdn, Med Oncol, Brisbane, Qld, Australia
[6] Aarhus Univ Hosp, Oncol, Aarhus, Denmark
[7] Sheba Med Ctr Tel HaShomer, Ctr Canc, Inst Oncol, Oncol,Ella Lemelbaum Inst Melanoma, Ramat Gan, Israel
[8] IRCCS San Martino IST, Oncol Med, Genoa, Italy
[9] Univ Sydney, Melanoma Inst Australia, Med Oncol, Sydney, NSW, Australia
[10] Univ Hosp Siena, Ctr Immunooncol, Med Oncol, Siena, Italy
[11] Univ Copenhagen, Herlev Hosp, Oncol, Herlev, Denmark
[12] Hadassah Hebrew Med Ctr, Sharett Inst Oncol, Med Oncol, Jerusalem, Israel
[13] Rambam Hlth Care Campus, Oncol, Haifa, Israel
[14] Laval Univ, Ctr Hosp Univ Quebec Res Ctr, Hematol, Quebec City, PQ, Canada
[15] Novartis, Oncol Clin Dev, E Hanover, NJ USA
[16] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[17] Ronald Reagan UCLA Med Ctr, Med Oncol, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1244O
引用
收藏
页码：442 / 442
页数：1
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
    Finn, Richard S.
    Edeline, Julien
    Bouattour, Mohamed
    Cheng, Ann-Lii
    Chan, Stephen Lam
    Yau, Thomas
    Garrido, Marcelo
    Knox, Jennifer J.
    Daniele, Bruno
    Zhu, Andrew X.
    Breder, Valeriy Vladimirovich
    Lim, Ho Yeong
    Ogasawara, Sadahisa
    Siegel, Abby B.
    Rahman, Ahmadur
    Wei, Ziwen
    Merle, Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [22] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [23] STARBOARD: Randomized phase III study of encorafenib (enco) plus binimetinib (bini) plus pembrolizumab (pembro) for first-line treatment of metastatic or unresectable locally advanced BRAF V600-mutant melanoma
    Schadendorf, D.
    Dummer, R.
    Robert, C.
    Ribas, A.
    Sullivan, R. J.
    Panella, T.
    Mckean, M. A.
    Santos, E. S.
    Brill, K.
    Polli, A.
    di Pietro, A.
    Ascierto, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S902 - S902
  • [24] Health-related quality of life (HRQoL) with pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355
    Cescon, D. W.
    Schmid, P.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C. E.
    Lipatov, O.
    Barrios, C. H.
    Perez Garcia, J. M.
    Iwata, H.
    Masuda, N.
    Torregroza Otero, M. A.
    Gokmen, E.
    Loi, S.
    Haiderali, A.
    Zhou, X.
    Guo, Z.
    Nguyen, A. Martin
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S197 - S198
  • [25] Association between baseline disease characteristics and relapse-free survival (RFS) in patients (pts) with BRAF V600-mutant resected stage III melanoma treated with adjuvant dabrafenib (D) plus trametinib (T) or placebo (PBO).
    Schadendorf, Dirk
    Dummer, Reinhard
    Hauschild, Axel
    Santinami, Mario
    Atkinson, Victoria
    Mandala, Mario
    Chiarion-Sileni, Vanna
    Larkin, James M. G.
    Nyakas, Marta
    Dutriaux, Caroline
    Haydon, Andrew Mark
    Mortier, Laurent
    Robert, Caroline
    Schachter, Jacob
    Ortmann, Christine-Elke
    De Jong, Egbert
    Gasal, Eduard
    Kefford, Richard
    Kirkwood, John M.
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Merle, Philippe
    Meyer, Tim
    Qin, Shukui
    Ikeda, Masafumi
    Xu, Ruocai
    Edeline, Julien
    Ryoo, Baek-Yeol
    Ren, Zhenggang
    Cheng, Ann-Lii
    Galle, Peter R.
    Kaneko, Shuichi
    Kumada, Hiromitsu
    Kamble, Shital
    Norquist, Josephine M.
    Mody, Kalgi
    Dubrovsky, Leonid
    Siegel, Abby B.
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 506 - 506
  • [27] A phase II multicenter, randomized, placebo controlled, double-blind study of CC-486 plus pembrolizumab (pembro) vs pembro plus placebo (PBO) in previously treated patients (pts) with locally advanced/metastatic non-small cell lung cancer (NSCLC).
    Levy, Benjamin Philip
    Giaccone, Giuseppe
    Besse, Benjamin
    Begic, Damir
    Wu, Xiaoling
    Fandi, Abderrahim
    Paz-Ares, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] A randomized phase Ib/II study of the selective small molecule Axl inhibitor bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
    Straume, O.
    Lorens, J. B.
    Gausdal, G.
    Gjertsen, B. T.
    Schuster, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [29] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
    Schadendorf, Dirk
    Long, Georgina V.
    Grob, Jean Jacques
    Nathan, Paul D.
    Ribas, Antoni
    Davies, Michael A.
    Flaherty, Keith T.
    Squires, Matthew
    Jaeger, Savina
    Powell, William
    Tan, Puay
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [30] PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K-mutant metastatic melanoma (MM) who received dabrafenib plus trametinib (D plus T) in the randomized phase 3 COMBI-v study.
    Schadendorf, Dirk
    Long, Georgina V.
    Grob, Jean Jacques
    Nathan, Paul D.
    Ribas, Antoni
    Davies, Michael A.
    Flaherty, Keith
    Squires, Matthew
    Jaeger, Savina
    Powell, William
    Tan, Puay
    Robert, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
12345